Cerebrospinal fluid biomarkers in Alzheimer's and Parkinson's diseases-From pathophysiology to clinical practice (Q38825497)

6 September 2017

1 reference

title

Cerebrospinal fluid biomarkers in Alzheimer's and Parkinson's diseases-From pathophysiology to clinical practice (English)

1 reference

6 September 2017

0 references

0 references

0 references

1

Kaj Blennow

1 reference

6 September 2017

4

Lucilla Parnetti

1 reference

6 September 2017

Leonardo Biscetti

2

1 reference

6 September 2017

Paolo Eusebi

series ordinal

3

1 reference

6 September 2017

language of work or name

English

0 references

publication date

4 May 2016

1 reference

6 September 2017

1 reference

6 September 2017

volume

31

1 reference

6 September 2017

issue

6

1 reference

6 September 2017

page(s)

836-847

1 reference

Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

CSF markers for incipient Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Core biological marker candidates of Alzheimer's disease - perspectives for diagnosis, prediction of outcome and reflection of biological activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Amyloid biomarkers in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Biomarkers in Alzheimer's disease drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Mild cognitive impairment: clinical characterization and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Neuropathological aspects of Alzheimer disease, Parkinson disease and frontotemporal dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Cognitive status correlates with neuropathologic stage in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Imaging the role of amyloid in PD dementia and dementia with Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Cerebrospinal fluid biomarkers and cognitive performance in non-demented patients with Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Determination of beta-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

α-Synuclein in Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Genomic and pharmacogenomic biomarkers of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Neuropathology of sporadic Parkinson's disease: evaluation and changes of concepts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Applicability of current staging/categorization of alpha-synuclein pathology and their clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Value of cerebrospinal fluid α-synuclein species as biomarker in Parkinson's diagnosis and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Low CSF levels of both α-synuclein and the α-synuclein cleaving enzyme neurosin in patients with synucleinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Phosphorylated α-synuclein in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Correlates of cerebrospinal fluid levels of oligomeric- and total-α-synuclein in premotor, motor and dementia stages of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Elevated levels of cerebrospinal fluid α-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Phosphorylated α-synuclein in Parkinson's disease: correlation depends on disease severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

CSF biomarkers and clinical progression of Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Ubiquitination of alpha-synuclein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Small ubiquitin-like modifier (SUMO) modification of natively unfolded proteins tau and alpha-synuclein

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Recent advances in α-synuclein functions, advanced glycation, and toxicity: implications for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson's disease pathogenesis and therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Posttranslational Modifications and Clearing of α-Synuclein Aggregates in Yeast

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Alpha-synuclein post-translational modifications as potential biomarkers for Parkinson disease and other synucleinopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Alpha-synuclein induces hyperphosphorylation of Tau in the MPTP model of parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

A novel, high-efficiency cellular model of fibrillar alpha-synuclein inclusions and the examination of mutations that inhibit amyloid formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Use of CSF α-synuclein in the differential diagnosis between Alzheimer's disease and other neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Increased CSF α-synuclein levels in Alzheimer's disease: correlation with tau levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Comparison of International Working Group criteria and National Institute on Aging-Alzheimer's Association criteria for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Injury markers predict time to dementia in subjects with MCI and amyloid pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

CSF biomarker variability in the Alzheimer's Association quality control program

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: an update from the Alzheimer's Association Global Biomarkers Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Mass spectrometry-based candidate reference measurement procedure for quantification of amyloid-β in cerebrospinal fluid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Round robin test on quantification of amyloid-β 1-42 in cerebrospinal fluid by mass spectrometry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Neocortical morphometry, lesion counts, and choline acetyltransferase levels in the age spectrum of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Alzheimer's presenile dementia, senile dementia of Alzheimer type and Down's syndrome in middle age form an age related continuum of pathological changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Cortical neuronal counts in normal elderly controls and demented patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Age and diagnostic performance of Alzheimer disease CSF biomarkers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Synaptic changes in Alzheimer's disease and its models

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Correlation of specific amyloid-β oligomers with tau in cerebrospinal fluid from cognitively normal older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Detection of single amyloid beta-protein aggregates in the cerebrospinal fluid of Alzheimer's patients by fluorescence correlation spectroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Aβ40 oligomers identified as a potential biomarker for the diagnosis of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

High-molecular-weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

A sensitive aβ oligomer assay discriminates Alzheimer's and aged control cerebrospinal fluid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Evaluating amyloid-β oligomers in cerebrospinal fluid as a biomarker for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Amyloid-β oligomer detection by ELISA in cerebrospinal fluid and brain tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Molecular machines governing exocytosis of synaptic vesicles

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Synaptic pathology in Alzheimer's disease: relation to severity of dementia, but not to senile plaques, neurofibrillary tangles, or the ApoE4 allele.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Neurogranin/RC3 enhances long-term potentiation and learning by promoting calcium-mediated signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Attenuation of protein kinase C and cAMP-dependent protein kinase signal transduction in the neurogranin knockout mouse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Oxidative damage of DJ-1 is linked to sporadic Parkinson and Alzheimer diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

CSF levels of DJ-1 and tau distinguish MSA patients from PD patients and controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Preparation and application of monoclonal antibodies against oxidized DJ-1. Significant elevation of oxidized DJ-1 in erythrocytes of early-stage Parkinson disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Patients with Amyotrophic Lateral Sclerosis and Other Neurodegenerative Diseases Have Increased Levels of Neurofilament Protein in CSF

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Cerebrospinal fluid biomarkers for Alzheimer disease and subcortical axonal damage in 5,542 clinical samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

α-Synuclein Is Degraded by Both Autophagy and the Proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Phenotype, diagnosis, and treatment of Gaucher's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Glucocerebrosidase is present in α-synuclein inclusions in Lewy body disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Selective loss of glucocerebrosidase activity in sporadic Parkinson's disease and dementia with Lewy bodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

The p.L302P mutation in the lysosomal enzyme gene SMPD1 is a risk factor for Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Changes in endolysosomal enzyme activities in cerebrospinal fluid of patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Synaptic failure and α-synuclein

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Increased CSF neurogranin concentration is specific to Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

iTRAQ and multiple reaction monitoring as proteomic tools for biomarker search in cerebrospinal fluid of patients with Parkinson's disease dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Non-motor signs in Parkinson's disease: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.26656

21 January 2018

Identifiers

DOI

10.1002/MDS.26656

1 reference

6 September 2017

1 reference